Throughout the world, cancer of esophagus is the sixth most common cause of cancer-related mortality.\[[@CIT1][@CIT2]\] Esophageal cancer is endemic in some regions of Iran.\[[@CIT3]--[@CIT5]\]

Many factors in patients with malignancy influence prognosis. High platelet count and thrombocytosis is seen in some patients with cancer.\[[@CIT6]--[@CIT8]\] Platelet count is inversely related to prognosis in various cancers; high count is associated with poor prognosis.\[[@CIT9][@CIT10]\] Whether thrombocytosis precedes malignant changes or follows it is not clear. Significance of platelet count in carcinoma of esophagus has been studied previously. High platelet counts were found to be associated with tumor progression and poor survival in esophageal cancer.\[[@CIT11]\] Platelets are the source of thymidine phosphorylase (TP). TP is known to be a platelet-derived endothelial cell growth factor which has potent angiogenic activity.\[[@CIT12]\] This substance is expressed at higher levels in a wide variety of solid tumors compared to normal tissues.\[[@CIT13]\] Increased TP expression and activity was found to be associated with poor prognosis in various solid tumor tissues.\[[@CIT14]\] Several different angiogenic factors produced by tumor cells and host cells may regulate angiogenesis during different steps of esophageal carcinogenesis. Findings suggest that angiogenic trigger is an early event in the development of invasive carcinoma.\[[@CIT15]\] High levels of TP are associated with increased micro-vascular density that facilitates tumor progression. All these factors, cumulatively, lead to poor prognosis in esophageal squamous cell carcinoma (SCC).\[[@CIT16][@CIT17]\] In this study, we investigated the relation between platelet count and prognostic factors in patients with esophageal cancer.

PATIENTS AND METHODS {#sec1-1}
====================

After institutional board review approval, all cases with esophageal cancer that underwent esophagectomy in a referral cancer institute in Tehran, Iran during a 5-year period (January 2002-December 2006) were studied retrospectively. Tumors located in the cervical esophagus and subcardia as well as administration of neoadjuvant therapy was considered as exclusion criteria of this study. Patients with lower esophageal tumor underwent transhiatal resection (Orringer technique) and those with mid- and upper-third esophageal tumor had transthoracic esophagectomy (Ivor-Lewis or Mckeown procedures).

Data were collected retrospectively from the patients' charts. The following information was recorded: preoperative platelet count (× 10^9^ /L), patient age, gender, site of tumor, presence of multiple cancers and clinicopathological characteristics including histological type, tumor size, depth of penetration (T according to TNM classification), lymph node involvement (N according to TNM classification), distant metastasis (M according to TNM classification), degree of differentiation, presence of vascular, lymphatic and perineural invasion. Since there were a limited number of cases in each T~1~ and T~2~ subgroups, the cases were classified as less penetrating tumors (T~1~ and T~2~) and more penetrating tumors (T~3~ and T~4~).

Platelet counts were presented as the mean ± standard deviation (×10^9^ /L). The relation between platelet count and clinicopathological characteristics was assessed with Chi-square, student's t and Pearson correlation tests. In all cases the probability of type 1 error \<0.05 was taken as the criterion of significance. Data handling and analysis were performed with SPSS software for Windows, version 11 (SPSS Inc., Chicago, IL).

RESULTS {#sec1-2}
=======

Three hundred and eighty-one cases with esophageal cancer were included. The mean age was 62.8±11.7 years. SCC constituted 93% and adenocarcinoma 7% of cases. Most of patients were in stage III, followed by stage II. Most tumors were located in the lower part of esophagus (60%). The details of clinicopathological findings were summarized in Tables [1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}.

###### 

Platelet count and clinicopathological variables in esophageal carcinoma

  Variable                    N (%)      Platelet count (×10^9^/L)   *P* value
  --------------------------- ---------- --------------------------- -----------
  Gender                                                             0.100
   Male                       201 (53)   239±69                      
   Female                     177 (47)   252±84                      
  Type                                                               0.003
   Squamous cell carcinoma    331 (93)   241±73                      
   Adenocarcinoma             24 (7)     290±111                     
  Location                                                           0.501
   Upper thoracic             6 (2)      263±99                      
   Middle thoracic            127 (38)   238±71                      
   Lower thoracic             201 (60)   247±80                      
  Degree of differentiation                                          0.803
   Well                       101 (31)   248±85                      
   Moderate                   164 (50)   246±76                      
   Poor                       63 (19)    240±71                      
  Lymphatic invasion                                                 0.756
   Present                    120 (43)   244±80                      
   Absent                     157 (57)   244±73                      
  Vascular invasion                                                  0.116
   Present                    134 (46)   252±85                      
   Absent                     157 (54)   237±71                      
  Perineural invasion                                                0.173
   Present                    67 (25)    232±62                      
   Absent                     203 (75)   245±80                      
  Multiple cancers                                                   0.205
   Present                    10 (3)     274±126                     
   Absent                     324 (97)   243±75                      

###### 

Platelet count and TNM classification in esophageal carcinoma

  Variable                 N (%)      Platelet count (×10^9^/L)   *P* value
  ------------------------ ---------- --------------------------- -----------
  Depth of penetration                                            0.474
   T1 and T2               70 (22)    239±63                      
   T3 and T4               246 (78)   246±77                      
  Lymph nodes metastasis                                          0.356
   Positive                152 (45)   251±83                      
   Negative                187 (55)   243±72                      
  Distant metastasis                                              0.756
   Present                 16 (5)     253±106                     
   Absent                  306 (95)   245±75                      

The mean platelet count was 245±76 (×10^9^ /L). There was no statistically significant correlation between platelet counts with gender, site of tumor, degree of penetration, lymph node involvement, distant metastasis, degree of differentiation, presence of vascular, lymphatic and perineural invasion and presence of simultaneous multiple cancers \[Tables[1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}\].

The platelet count in patients with adenocarcinoma was significantly higher than patients with SCC, with a mean difference of 48±16 (×10^9^ /L) (*P*= 0.003) \[[Table 1](#T0001){ref-type="table"}\]. The grade and stage of tumors were not statistically different between SCC and adenocarcinoma histology \[[Table 3](#T0003){ref-type="table"}\].

###### 

Comparison of clinicopathological variables between squamous cell carcinoma and adenocarcinoma of esophagus

  Variable                    Squamous cell carcinoma   Adenocarcinoma   *P* value
  --------------------------- ------------------------- ---------------- -----------
  Depth of penetration                                                   0.754
   T~1~ and T~2~              62 (22)                   4 (25)           
   T~3~ and T~4~              224 (78)                  12 (75)          
  Lymph nodes metastasis                                                 0.146
   Positive                   130 (43)                  12 (60)          
   Negative                   170 (57)                  8 (40)           
  Distant metastasis                                                     0.205
   Present                    12 (4)                    2 (11)           
   Absent                     272 (96)                  17 (89)          
  Degree of differentiation                                              0.061
   Well                       90 (31)                   8 (40)           
   Moderate                   149 (51)                  5 (25)           
   Poor                       51 (18)                   7 (35)           
  Lymphatic invasion                                                     0.288
   Present                    105 (43)                  8 (57)           
   Absent                     141 (57)                  6(43)            
  Vascular invasion                                                      0.389
   Present                    115 (45)                  10 (56)          
   Absent                     140 (55)                  8 (44)           
  Perineural invasion                                                    0.510
   Present                    57 (24)                   5 (31)           
   Absent                     181 (76)                  11 (69)          

Figures in parentheses are in percentage

There was a weak linear correlation between platelet count and tumor size (*P* = 0.03, Pearson correlation coefficient: 0.16) \[[Figure 1](#F0001){ref-type="fig"}\].

![Correlation between platelet count and tumor size](SJG-17-134-g001){#F0001}

DISCUSSION {#sec1-3}
==========

We defined thrombocytosis as a platelet count greater than 400 (×10^9^ /L).\[[@CIT8]\] In this regard, only 3.4% of our patients had thrombocytosis. In fact the mean platelet count of patients in this study was near to lower limit of normal range. Previous studies have shown that both thrombocytosis and thrombocytopenia are associated with unfavorable prognosis.\[[@CIT6]--[@CIT10]\] According to one study, patients with TP-positive esophageal tumors have a poorer prognosis than those with TP-negative tumors. Additionally, TP inhibition suppresses tumor growth by increasing the proportion of apoptotic cells and probably inhibiting angiogenesis. Absence of thrombocytosis may be interpreted as TP-negative tumor (inhibition of TP expression) leading to a better prognosis.\[[@CIT18]\] Absence of thrombocytopenia is also shown to be associated with better prognosis in patients with esophageal SCC without tumor obstruction.\[[@CIT19]\] However, our patients were not thrombocytopenic either.

Platelet count in our series showed no significant association with major prognostic variables for esophageal cancer including gender, site of tumor, degree of penetration, lymph node involvement, distant metastasis, degree of differentiation, presence of vascular, lymphatic and perineural invasion and presence of simultaneous multiple cancers; except for a weak linear correlation with tumor size. This finding is likely in favor of TP-negative tumors (absence of TP expression) being the dominant pattern in our patients. Studies indicate that platelet counts are significantly increased in patients with large tumors, deep tumors, those with nodal involvement and patients with distant metastasis.\[[@CIT11]\] However, there are also reports indicating that higher TP levels expressed by esophageal tumors do not correlate with the histopathological grading of tumor, depth of tumor invasion and lymph node metastasis.\[[@CIT20]\] We did not measure TP levels in our patients so we cannot determine whether they were TP-negative or TP-positive but with no correlation.

We found that patients with adenocarcinoma of esophagus had a significantly higher platelet count compared to those with SCC (*P* = 0.003), in the presence of similar stage and grade of tumors \[[Table 3](#T0003){ref-type="table"}\]. We could not find any similar report. Adenocarcinoma developing at other sites including kidney, colon and female reproductive organs express thrombocytosis.\[[@CIT7][@CIT8][@CIT10]\] A high preoperative platelet count was an independent prognostic variable for mortality in patients with adenocarcinoma of colon and rectum.\[[@CIT8]\] The correlation of higher platelet counts, in adenocarcinoma of esophagus, with prognosis must be defined in further studies. The clinical significance of this finding with regard to therapeutic decisions may then be decided.

The main limitation of this study was gathering of data retrospectively. Another important issue was that we did not measure TP level. The high incidence of SCC (93%) in comparison to adenocarcinoma (7%) may have had an adverse effect on statistical analysis.

It may be concluded that platelet count may not always correlate with prognostic variables in SCC of esophagus. However, platelet count may be significantly higher in adenocarcinoma of esophagus, as found in this study.
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